| Publisher’s Note: Join us September 11-14 in Philadelphia for Digital Pharma East! We’re excited to announce our opening keynote, none other than Dustin Garis, world-renowned brand innovator, customer experience pioneer and Chief Troublemaker. Register today for the ultimate marketing event in the life sciences industry. |
Today's Big NewsJul 31, 2023 |
|
October 5-6, 2023 San Diego, CA Join us at the Fierce Medical Affairs Strategic Summit West and hear industry-leading speakers from Amgen, Abbott, Bayer, Gilead, Janssen, Otsuka, Daiichi Sankyo, and many more. Register now with early bird rates and save $200. .png) |
|
| By Nick Paul Taylor Sumitomo Pharma and Otsuka’s plan to turn ulotaront into a blockbuster growth driver is on the ropes. A pair of phase 3 schizophrenia clinical trials of the candidate missed their primary endpoints, leaving the partners looking to a “high placebo response” for evidence that the asset has a future in the disease. |
|
|
|
| Philadelphia, PA |  |
|
|
By James Waldron Okyo Pharma announced plans to sell off some of its shares on Friday, but the ophthalmology-focused biotech clearly had a change of heart over the weekend as the offer was withdrawn this morning over “changing market conditions.” |
By Nick Paul Taylor Annexon has found more to love in its failed phase 2 eye disease clinical trial. Months after framing the study as a success in its top-line results, the biotech has returned with further analyses that it pitched as evidence ANX007 is a promising, differentiated geographic atrophy candidate. |
By James Waldron MyMD Pharmaceuticals’ lead asset has hit all primary and secondary endpoints in a mid-phase study of age-related inflammation, setting the company up to begin phase 3 talks with the FDA. |
By Helen Floersh Researchers have identified another potential gene therapy for treating chronic pain, this time by indirectly targeting a key sodium ion channel. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Andrea Park GE HealthCare warned healthcare providers that tens of thousands of TruSignal pulse oximeters may put hospitalized patients at risk of further injury. |
By Kevin Dunleavy A study of FDA advisory committee meetings between 2010 and 2021 shows that the regulator leaned heavily toward approval. When a panel recommended approval, the FDA agreed 97% of the time. When a panel recommended a thumbs-down, however, the FDA complied only 67% of the time. |
By Anastassia Gliadkovskaya The company will donate $25 to UCLA Mattel Children’s Hospital for every OB-GYN appointment booked on its platform through Aug. 21, up to $10 million total. |
By Angus Liu Takeda's targeted non-small cell lung med Exkivity has failed in a phase 3 trial in newly diagnosed patients, just days after Johnson & Johnson touted a win for its rival EGFR inhibitor. |
By Dave Muoio The American Hospital Association, American Medical Association and Blue Cross Blue Shield Association penned a joint letter highlighting "conflicting" prior authorization electronic standards and workflows they say will bring industry confusion and unnecessary burden. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we revisit an episode on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription. |
|
|---|
|
|
Whitepaper Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| |
|
